Vaxcyte, Inc. $PCVX Stock Position Increased by Intech Investment Management LLC

Intech Investment Management LLC boosted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 44.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 89,212 shares of the company’s stock after buying an additional 27,384 shares during the quarter. Intech Investment Management LLC owned 0.07% of Vaxcyte worth $3,369,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Vaxcyte by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock worth $19,409,000 after buying an additional 41,034 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of Vaxcyte in the 1st quarter worth $226,000. Jones Financial Companies Lllp lifted its holdings in shares of Vaxcyte by 113,702.7% during the first quarter. Jones Financial Companies Lllp now owns 166,152 shares of the company’s stock valued at $6,274,000 after purchasing an additional 166,006 shares during the last quarter. Polar Asset Management Partners Inc. acquired a new position in shares of Vaxcyte in the 1st quarter valued at $378,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Vaxcyte by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,081 shares of the company’s stock worth $3,218,000 after purchasing an additional 3,547 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on PCVX shares. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research report on Friday. They issued a “neutral” rating and a $38.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $106.25.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $32.17 on Friday. The firm has a market cap of $4.18 billion, a price-to-earnings ratio of -7.83 and a beta of 1.04. The stock has a 50-day simple moving average of $33.16 and a 200-day simple moving average of $39.01. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.10). During the same period in the previous year, the business posted ($1.10) earnings per share. As a group, equities research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.